Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma [ID1444]
In development [GID-TA10477] Expected publication date: 22 September 2021
Search results
669 results
-
-
NBTXR-3 for treating soft tissue sarcoma [ID1050]
In development [GID-TA10226] Expected publication date: TBC
-
Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]
In development [GID-TA10739] Expected publication date: 25 May 2022
-
Melanoma (metastatic) - talimogene laherparepvec [ID508]
In development [GID-TAG509] Expected publication date: 28 September 2016
-
Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]
In development [GID-TAG414] Expected publication date: TBC
-
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)
In development [GID-MT526] Expected publication date: TBC
-
Tofacitinib for treating juvenile idiopathic arthritis [ID2718]
In development [GID-TA10706] Expected publication date: 20 October 2021
-
Percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica
In development [GID-IP2803] Expected publication date: TBC
-
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596
In development [GID-TA10497] Expected publication date: TBC
-
Personal, social, health and economic education focusing on sex and relationships and alcohol education
In development [GID-PHG0] Expected publication date: TBC
-
Breast cancer (advanced or metastatic) - lapatinib [ID20]
In development [GID-TAG387] Expected publication date: TBC
-
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]
In development [GID-TA10523] Expected publication date: TBC
-
Nivolumab for adjuvant treatment of oesophageal or gastro-oesophageal junction cancer [ID1676]
In development [GID-TA10743] Expected publication date: 17 November 2021
-
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development [GID-TA10555] Expected publication date: TBC
-
Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]
In development [GID-TA10552] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]
In development [GID-TA10234] Expected publication date: TBC
-
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]
In development [GID-TA10046] Expected publication date: 22 November 2017
-
Maintaining normothermia using temperature modulation devices to improve outcomes after stroke or subarachnoid haemorrhage
In development [GID-IPG10153] Expected publication date: 28 July 2021
-
Managing common infections - antimicrobial prescribing guidelines
In development [GID-NG10050] Expected publication date: TBC
-
Third molars (impacted) - prophylactic removal [ID898]
In development [GID-TAG525] Expected publication date: TBC
-
Dementia (non-Alzheimer) - new pharmaceutical treatments [ID380]
In development [GID-TAG369] Expected publication date: TBC
-
Peramivir for treating influenza [ID828]
In development [GID-TA10155] Expected publication date: TBC
-
Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]
In development [GID-TAG507] Expected publication date: TBC
-
Melanoma (resected stage IV, high risk stage III) - ipilimumab (adjuvant) [ID721]
In development [GID-TAG479] Expected publication date: TBC
-
Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]
In development [GID-TA10363] Expected publication date: TBC
-
Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]
In development [GID-TA10026] Expected publication date: TBC
-
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]
In development [GID-TAG321] Expected publication date: TBC
-
Microthane implants for breast reconstruction or breast augmentation (discontinued)
In development [GID-MT267] Expected publication date: TBC
-
Multiple sclerosis - sativex [ID387]
In development [GID-TAG368] Expected publication date: TBC
-
Thrombophilia [ID393]
In development [GID-TAG374] Expected publication date: TBC
-
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683
In development [GID-TA10537] Expected publication date: TBC
-
Osteoarthritis - naproxcinod [ID417]
In development [GID-TAG426] Expected publication date: TBC
-
Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention
In development [GID-IP1238] Expected publication date: TBC
-
Community nursing care settings
In development [GID-SGWAVE0700] Expected publication date: TBC
-
Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604
In development [GID-TA10518] Expected publication date: TBC
-
Maternal and child nutrition
In development [GID-NG10191] Expected publication date: 22 November 2023
-
Multiple sclerosis (relapsing-remitting) - laquinimod [ID560]
In development [GID-TAG337] Expected publication date: TBC
-
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Technology appraisal [TA582] Published: 24 May 2019
-
Masitinib for treating amyotrophic lateral sclerosis [ID967]
In development [GID-TA10157] Expected publication date: TBC
-
Secukinumab for treating plaque psoriasis in children and young people [ID1669]
In development [GID-TA10554] Expected publication date: 20 October 2021
-
Workplace health for employees with disabilities and long-term conditions
In development [GID-PHG58] Expected publication date: TBC
-
Selpercatinib for treating advanced thyroid cancer with RET alterations [ID3744]
In development [GID-TA10614] Expected publication date: TBC
-
Peezy Midstream for urine collection (MT446)
In development [GID-MT538] Expected publication date: TBC
-
Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]
In development [GID-TAG424] Expected publication date: TBC
-
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]
In development [GID-TA10570] Expected publication date: 17 November 2021
-
Juvenile idiopathic arthritis - abatacept [ID27]
In development [GID-TAG402] Expected publication date: TBC
-
Diagnostic services
In development [GID-CGWAVE0773] Expected publication date: TBC
-
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]
In development [GID-TA10561] Expected publication date: 30 June 2021
-
Accident and emergency departments
In development [GID-SGWAVE0762] Expected publication date: TBC
-
Magnetic resonance therapy for knee osteoarthritis
In development [GID-IPG10159] Expected publication date: 25 August 2021